Change of Registered Office

Summary by AI BETAClose X

SkinBioTherapeutics plc announced a change to its registered office address, effective October 16, 2026, moving to Driffield, East Yorkshire. This relocation follows a review of office requirements and the decision not to renew the lease at its current Newcastle location, reflecting the company's commitment to maintaining a disciplined cost base and an efficient operational structure as its UK-based team operates across a wider geographical area.

Disclaimer*

SkinBioTherapeutics PLC
15 October 2026
 

A blue text on a white background Description automatically generated 

 

SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group")

Change of Registered Office Address

15 October 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that its registered office address will change with effect from 16 October 2026 to Unit 75, Windmill Works, Warfield Road, Kelleythorpe Industrial Estate, Driffield, East Yorkshire YO25 9FQ.

The change follows a review of the Company's office requirements ahead of the renewal of its existing lease at The Core in Newcastle. With the Company's UK-based team now operating across a wider geographical area, the Board has taken the opportunity to reassess its office requirements to better reflect the evolving needs of the business and has decided not to renew the lease.

The decision is consistent with the Company's ongoing commitment to maintaining a disciplined approach to its cost base and ensuring that its operational structure remains efficient and appropriate for the business.

-Ends-

For more information please contact:

SkinBioTherapeutics plc
Alyson Levett, Chair
Rachel Parsonage, CEO

ir@skinbiotix.com

 

Singer Capital Markets (Nominated Adviser & Broker)
Alex Bond
Sara Hale
Patrick Weaver

+44 (0) 020 7496 3000

 

Vigo Consulting
Melanie Toyne-Sewell
Rozi Morris

+44 (0) 20 7390 0230
SkinBio@vigoconsulting.com

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life sciences company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Company's strategic approach to skin health is via two routes - tackling skin issues from the 'outside in' and the 'inside out'. The 'outside in' approach is represented by topical creams, and from the 'inside out', via oral supplement solutions which impact the skin via different axes such as the gut and the brain.

SkinBio's products and services are developed through evidence-based science and commercially focused innovation with the aim of supporting skin health, well-being, repair and beauty. SkinBio also has a contract manufacturing and distribution arm related to skin health and other healthcare products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.SkinBioTherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings